This article reviews what is known about the role of the IL 23–IL 17 immune pathway at different stages in the development and progression of chronic immune-mediated inflammatory diseases, in particular rheumatoid arthritis and spondyloarthritis. The author draws on findings from disease-specific animal models and humanex vivostudies as well as data from clinical trials of therapies targeting the IL 23–IL 17 axis.
